Stocktoria

Alphatec Holdings, Inc. ATEC

Nasdaq · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2006-06-02 · LEI

Alphatec Holdings, Inc. (ATEC) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $764.2M at a -18.8% net margin.

Chart by TradingView
42/100
Stocktoria Quality Score · grade C
6/9
Piotroski F — financial health
-4.63
Altman Z″ — distress risk · distress
Dividend yield · no dividend
-3.42
Beneish M-score — earnings quality · low

Quality score trend · recomputed for each fiscal year

Piotroski F /9
5 4 4 3 5 3 3 4 4 6 2016201720182019202020212022202320242025

Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.

$9.63 as of 2026-08-01 · -39.4% 1y
$7.75$22.5552-wk

Beneish M-score: -3.42 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.

Market cap USD$1.4B
Net margin 5y avg-37.2%
Return on equity 5y avg-523.3%
Beta0.87
Employees913

Analyst price target

$16.73 +73.7% vs last
· 11 analysts
target range $11.00 – $24.00

Wall Street analyst consensus — a sentiment gauge, not our scoring.

Smart money · insiders, last 12 months

Insiders net sold -$3.2M on the open market · 6 trades

Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.

Revenue trend · last 10y · up

How it ranks in Manufacturing · percentile among 1957 companies

Piotroski Fstronger than 78%
Net marginstronger than 36%
Return on equitystronger than 1%
Revenue growthstronger than 84%

Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.

Piotroski F breakdown · 6/9 tests passed

Altman Z″ components · distress zone

ComponentValue
Working capital / assets0.293
Retained earnings / assets-1.8
EBIT / assets-0.104
Equity / liabilities0.016

Sector peers · similar-size Manufacturing companies compare side by side →

TickerCompanyPiotroski FAltman Z″P / ERevenue growth
ATECAlphatec Holdings, Inc.6/9-4.63+25%
IRTCiRhythm Holdings, Inc.5/90.78+26.2%
OFIXOrthofix Medical Inc.5/91.02+2.9%
NVCRNovoCure Ltd3/9-2.29+8.3%
INSPInspire Medical Systems, Inc.6/99.889.1+13.6%
UFPTUFP TECHNOLOGIES INC7/9628.7+19.5%
BVSBioventus Inc.8/90.5435.9-0.9%

All Manufacturing companies →

About Alphatec Holdings, Inc.

Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. The company manufactures and sells implants, instruments, imaging equipment, and spare parts. It offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; SafeOp Neural InformatiX System that automates electromyographic, somatosensory evoked potential, and motor evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissue; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. The company was founded in 1990 and is headquartered in Carlsbad, California.

FAQ

Is ATEC financially healthy?

Alphatec Holdings, Inc.'s Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.

Does ATEC pay a dividend?

No, Alphatec Holdings, Inc. does not currently pay a dividend.

How profitable is ATEC?

In FY2025, Alphatec Holdings, Inc. had a net margin of -18.8% and a return on equity of -1153.7%.

What is the analyst price target for ATEC?

The average Wall-Street price target for Alphatec Holdings, Inc. is $16.73, about 73.7% above the recent price, from 11 analysts.

Is ATEC a good stock to buy?

Stocktoria doesn't give buy or sell advice, but here is the data on Alphatec Holdings, Inc.: a Piotroski F-score of 6/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.